EDMONTON, Alberta--(BUSINESS WIRE)--Feb. 16, 2006--ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it has closed a brokered private placement equity financing which will result in the issuance of 10,909,090 units at a price of $1.10 per unit for gross proceeds to the Company of $12,000,000. Each unit consists of one common share and one common share purchase warrant. Each common share purchase warrant entitles the holder to purchase one common share of ViRexx at a price of $1.50 for a period of two years from the date of issuance.
